Should have been written as 'meaningless sales"?
Printable View
MDX health have had a similar reimbursement experience with their prostate product and have been reimbursed for previous years tests. I look forward to a similar situation possibly happening with PEB. But time will tell. Much easier to sell milk or software unfortunately. Hopefully PEB turn into a CUV situation, surprised nobody above seems to be on that winner.
Bio tech is expensive, PEB currently have a new clinical/user trial for their monitor product that includes
Urologists in Urology Centers of Alabama
Urology Center of Grove Hill, One Lake Street
Florida Urology Associates
Idaho Urologic Institute
Delaware Valley Urology, LLC
Premier Medical Group of the Hudson Valley
Weill Cornell Medical College, Department of Urology
Penn State Hershey Medical Center and College of Medicine
UT Southwestern Medical Center
Suppose i could invest in FBU. Didnt they just loose 400 million in a year.
or even better Summerset who just had 200+ million slugged off their Mcap in the space of a week.
Good luck to all,
It's been at least three months since PEB last diluted our holdings with another massive discounted insto offer hasn't it? Where's my regularly scheduled devaluation?
Be thankful that the sucker institutions are there to prop up this sorry excuse of a biomed company!
Last placement and capital raising was done at 34c - that's 20% down the drain for them in 2.5 months! :t_down:
You can actually buy in cheaper than the sucker instos! Not that it's that hard - the instos are so punch drunk with PEB-induced losses that they would be willing to roll with the next placement (due in September 2020 at this stage).
Reporting next month - there's a few of us who always look forward to what excuses and stories DD & his board are going to come up with to explain away yet another disappointing delay to the promised $100m revenues!
This time, it probably will be because of the Mexican border controversy - cannot get health workers, see? :D
https://www.healio.com/hematology-on...ncer-detection
And of course PEB would like you to believe that they have the best in the industry!
Never mind the fact that it is clear that the top universities and med clinics obviously do not think so!
Tick ... tick ....
http://nzx-prod-s7fsd7f98s.s3-websit...925/277893.pdf
Investor Update must be due and really, there are only 2 questions or update investors and shareholders need :
1. What happened to Kaiser?
2. What happened to the CMS reimbursement rate, 6 months from when PEB made the exciting announcement from the ever exuberantly capital raising excited DD?
"..... The rate, set by the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests, will be open for public comment until 22 October 2018 and will be published in the Clinical Laboratory Fee Schedule in November 2018 and effective from 1 January 2019."
Oops - it's April 2019!
The call has gone out for new Directors.
Would love some info on the board decisions:
1. Who signed off on the receivables v actual revenue farce and retreat.
2. Were going to be $100M by 2018 (expired) with no grounding in reality.
3. Raising $150M for international expansion based on flimsy market research.
4. DD expenses out of reality with market traction
5. Poor performing sales team
6. Potential dividends (lol) estimate. I am guessing 2075 or after?
Thanks
Pretty much pick any previous announcement... and the questions flow. Here's Feb 1 2018
1. Where are they are with Raffles and expansion into S.E.Asia?
2. How are the "User Programmes" (studies) progressing in Singapore; especially "transitioning" these to commercial customers (i.e. tests that are actually paid for)?
3. How much is the Singapore 'base' costing PEB? What other sales 'achievements' have they to report more than a year later?